Viral Kansara
Vice President, Preclinical Research Clearside Biomedical
Dr Viral Kansara joined Clearside Biomedical as Vice President, Discovery. Viral was formerly Head of Ocular Drug Discovery and Drug Delivery Laboratory in the Ophthalmology department at Novartis Institutes for Biomedical Research, Inc. He has over 12 years of combined industry and academic experience and expertise in the field of ocular drug discovery, delivery, and drug development. At Novartis, Dr. Kansara’s lab focused on the discovery and development of novel treatment therapies for blinding diseases such as macular degeneration, diabetic retinopathy, neurodegeneration, and glaucoma. He leads a team of scientists responsible for evaluating novel ocular drug delivery technologies, identifying new targets, and developing pharmacology models. Dr. Kansara has published and presented his research at numerous national and international conferences.
Seminars
- Evaluating how novel ocular delivery approaches can overcome barriers to targeting complement pathways in retinal disease
- Leveraging PK/PD insights to optimize therapeutic exposure, dosing strategies, and clinical outcomes in ophthalmology
- Advancing complement and gene therapy approaches for AMD and other neurodegenerative eye diseases through targeted drug delivery
NEW SPEAKING COMPANY
